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Human epidermal growth factor receptor 2 (HER2) and topoisomerase II alpha (TOP2A) genes have been proposed
as predictive biomarkers of sensitivity to anthracycline chemotherapy. Recently, chromosome 17 centromere
enumeration probe (CEP17) duplication has also been associated with increased responsiveness to
anthracyclines. However, reports are conflicting and none of these tumor markers can yet be considered a
clinically reliable predictor of response to anthracyclines. We studied the association of TOP2A gene alterations,
HER2 gene amplification, and CEP17 duplication with response to anthracycline-based neoadjuvant chemotherapy
in 140 patients with operable or locally advanced breast cancer. HER2 was tested by fluorescence in situ
hybridization and TOP2A and CEP17 by chromogenic in situ hybridization. Thirteen patients (9.3%) achieved
pathologic complete response (pCR). HER2 amplification was present in 24 (17.5%) of the tumors. TOP2A
amplification occurred in seven tumors (5.1%). CEP17 duplication was detected in 13 patients (9.5%). CEP17
duplication correlated with a higher rate of pCR [odds ratio (OR) 6.55, 95% confidence interval (95% CI) 1.25-34.29,
P = .026], and analysis of TOP2A amplification showed a trend bordering on statistical significance (OR 6.97, 95%
CI 0.96-50.12, P= .054). TOP2A amplification and CEP17 duplication combined were strongly associated with pCR
(OR 6.71, 95% CI 1.66-27.01, P = .007). HER2 amplification did not correlate with pCR. Our results suggest that
CEP17 duplication predicts pCR to primary anthracycline-based chemotherapy. CEP17 duplication, TOP2A
amplifications, and HER2 amplifications were not associated with prognosis.
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Predicting response to anthracycline-based therapy is a central challenge
in patients with breast cancer. Several randomized studies have shown that
anthracycline-based adjuvant therapy produces amodest improvement in
survival in patients with early-stage breast cancer [1]. In addition, it has
been shown that incorporation of taxanes further improves pathologic
complete response (pCR) in the neoadjuvant setting [2–7]. However, the
risk of serious side effects must be considered and predictive factors are
needed to help clinicians select themost appropriate drug for each patient.
To date, no specific biomarkers have been identified to predict tumor
response to anthracycline-based chemotherapy.
The human epidermal growth factor receptor 2 (HER2) and topoisome-
rase II alpha (TOP2A) genes have been proposed as markers of sensitivity
to anthracycline chemotherapy. Although several studies have reported an
association between HER2 amplification with anthracycline sensitivity
[8–13], only two of these were statistically significant [10,13]. In vitro and
in vivo studies indicate that HER2 positivity alone does not alter
anthracycline sensitivity [14] and the underlying mechanism remains
elusive. The TOP2A gene, located at 17q12-q21, close to the HER2
gene, encodes TOP2A, a key enzyme in DNA replication and the
molecular target of anthracyclines [15,16]. When HER2 is amplified,
genes situated around 17q21, such as TOP2A gene, may be either co-
amplified or deleted [17]. Because of this physical proximity, some
researchers have proposed that the link between HER2-positive disease
and anthracycline sensitivity is the presence of TOP2A alterations
(amplifications and deletions) rather than HER2 amplifications [18,19].
However, the results of these studies have not always been consistent [20].
Given the location of HER2 and TOP2A on chromosome 17, recent
reports have focused on the predictive role of other molecular alterations
localized within the 17q21 region, including alterations in key genes such
as HER1-3 [21], p53 [22], and BRCA1 [23], and variations in the copy
number of subchromosomal regions, including the chromosome 17
centromere (CEP17) duplication [21]. On the basis of recent data from
array comparative genomic hybridization, CEP17 duplication is defined
as increased copy number of CEP17 [21] rather than polysomies of the
whole chromosome 17 [24,25]. CEP17 duplication has been described as
a marker of genomic instability [26] and has received a great deal of
attention as a potential predictor of anthracycline benefit [21,27].
We hypothesized that CEP17 duplication is associated with a higher
response to neoadjuvant chemotherapy. We explored the association of
CEP17 duplication and TOP2A alterations with response to anthracy-
cline-based neoadjuvant therapy. We studied a cohort of patients
with early or locally advanced breast cancer treated with anthracycline-
based primary chemotherapy, and we chose pCR as a surrogate marker
of chemosensitivity.
Materials and Methods
Ethics Statement
This study was conducted according to the Declaration of Helsinki
principles, with approval from the Clinical Research Ethics Committee
at Institut d'Investigacions Biomèdiques Sant Pau. Written informed
consent was obtained from all patients.
Study Design and Patients
We retrospectively studied 140 consecutive patients with stage II or
III breast cancer who received anthracycline-based neoadjuvant
chemotherapy in our hospital between 1993 and 2010. All patients
had confirmed diagnosis based on histopathology of biopsy and noneof them had prior treatment with surgery, chemotherapy, or radiation.
Our study included patients with HER2-positive carcinomas treated
before the approval of trastuzumab in 2006. The study excluded
patients with bilateral or inflammatory tumors. Fifty-five patients
received neoadjuvant treatment with anthracyclines alone [FEC75:
fluorouracil (600 mg/m2), epirubicin (75 mg/m2), and cyclophospha-
mide (600 mg/m2) given every 3 weeks for four to six cycles, n = 40, or
FAC60: fluorouracil (500 mg/m2), doxorubicin (60 mg/m2), and
cyclophosphamide (500 mg/m2) given every 3 weeks for four to six
cycles, n = 15] between 1993 and 2002. Eighty-five patients received
neoadjuvant treatmentwith anthracyclines in combination with taxanes
[EC-D: epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2)
given every 3 weeks for four cycles followed by docetaxel (100 mg/m2)
every 3 weeks for four cycles] from 2003 to 2010. Patients were staged
according to the tumor-node-metastasis (TNM) system. Clinical
response was assessed by palpation, breast ultrasound, mammography,
and/or magnetic resonance imaging before systemic therapy and before
curative surgery. Clinical responses were evaluated according to the
response evaluation criteria in solid tumors (RECIST) criteria [28] every
two cycles. Patients treated with FEC75 or FAC60with partial response
received surgical treatment after four cycles of chemotherapy and two
additional cycles of FEC75 or FAC60 were administered after surgery.
Patients treated with EC-D underwent breast surgery after completion
of chemotherapy. Patients with positive hormone receptor tumors
received radiotherapy and endocrine therapy. The extent of residual
disease was measured in the surgical specimen. The primary endpoint
for this study was pCR defined as the absence of invasive cancer in the
breast and axillary lymph nodes at the time of definitive surgery. The
secondary endpoints for the study were disease-free survival (DFS) and
overall survival (OS). Patients were followed up according to the breast
cancer guidelines.
Tumor Samples and Tissue Microarrays
We analyzed 140 representative formalin-fixed, paraffin-embedded
tumor core biopsies obtained before neoadjuvant treatment. Paraffin
blocks were stored at room temperature. Samples were identified only
by an identification number assigned to each patient. A stained
section of each tumor sample was prepared to confirm the diagnosis
and to identify representative tumor areas. Tissue microarrays were
prepared from formalin-fixed, paraffin-embedded tissue taken from
three representative areas of each tumor. Serial 5-μm sections were
obtained for immunohistochemical, fluorescence in situ hybridization
(FISH), and chromogenic in situ hybridization (CISH) analyses.
Immunohistochemistry
Prediluted antibodies for estrogen receptor (ER; clone EP1),
progesterone receptor (PR; clone 636) and Ki67 (clone MIB-I) were
obtained from Dako (Glostrup, Denmark). Sections were processed
in a PT Module using Dako high pH buffer (Dako) for
deparaffinization and antigen retrieval. Sections for the Ki-67 study
were processed with Dako low pH buffer. All immunohistochemical
stains were performed in an Autostainer Link using the EnVision
method (Dako). HER2 overexpression was analyzed using the
HercepTest assay (Dako). Tumors were classified as ER or PR
positive when at least 1% of the tumor cells showed staining in the
nuclei cells [29]. HER2 was considered overexpressed when a
uniform intense (3+) membrane staining was present in N30% of
invasive tumor cells [30]. The percentage of Ki67-stained nuclei was
evaluated independently of the intensity and its positivity cutoff value
Table 1. Basic Patient and Tumor Characteristics.
Variable n (%)
N 140
Age, years Mean ± SD 53.7 ± 13.5
Median (range) 51 (25.5-86.1)
Menopausal status Premenopausal 65 (46.4)
Postmenopausal 75 (53.6)
Tumor stage II 50 (35.7)
III 90 (64.3)
Tumor status T2 39 (27.9)
T3 42 (30.0)
T4 59 (42.1)
Node status N0 47 (33.6)
N1 63 (45.0)
N2 26 (18.6)
N3 4 (2.9)
Tumor grade 1 11 (7.9)
2 63 (45.0)
3 66 (47.1)
ER Positive 87 (62.1)
Negative 53 (37.9)
PR Positive 68 (48.6)
Negative 72 (51.4)
Ki67 status b20% 74 (42.9)
≥20% 60 (52.9)
Missing data 6 (4.3)
HER2 Normal 113 (81)
Amplification 24 (17)
Missing data 3 (2)
TOP2A Normal 124 (89)
Amplification 7 (5)
Deletion 6 (4)
Missing data 3 (2)
Neoadjuvant therapy FEC75/FAC60 55 (39.3)
EC-D 85 (60.7)
Surgical treatment Mastectomy 88 (62.9)
Lumpectomy 52 (37.1)
Pathologic response Complete 13 (9.3%)
Residual disease 127 (90.7)
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immunostainings, and discordant results were reviewed to reach
an agreement.
In situ Hybridization Analyses
HER2 gene status was confirmed for all patients by FISH.
TOP2A gene status was evaluated by CISH and FISH in equivocal
cases. A good correlation of the results for TOP2A obtained by
FISH or CISH has been previously reported [32]. We used the
HER2 FISH pharmDX (Dako) and the TOP2A FISH pharmDX
(Dako) assays, respectively. The CISH assay was performed using
Dako dual color assay (Dako). All tests were performed following
the manufacturer's recommendations. Fluorescence signals were
evaluated using an Olympus BX51 fluorescent microscope and
appropriate filter sets. The assessment of FISH results for TOP2A
and HER2 was performed in ≥60 nuclei per case. TOP2A gene
status was assessed by CISH in ≥30 tumor cells per case. HER2
gene amplification was defined when the ratio HER2/CEP17 was
≥2 in accordance with the manufacturer’s recommendations.
TOP2A amplification was considered when the ratio TOP2A/
CEP17 was ≥2 and TOP2A deletion was considered when the ratio
TOP2A/CEP17 was b0.8. We use the term CEP17 duplication
throughout the text as defined previously [21]. The cutoff value for
CEP17 duplication was determined as N1.86 observed CEP signals
per cell [21,26].
Statistical Analyses
DFS was defined as the time from initiation of treatment to date
of first relapse (local, regional, contralateral or metastatic), second
primary cancer, or death resulting from any cause (whichever
occurred first). OS was defined as the time from sample collection to
death resulting from any cause. Patients lost to follow-up were
censored at the last contact. Quantitative variables between groups
were compared using the Student’s t test, and categorical variables
were compared using the Chi-square or Fisher exact test. The
univariable association between variables and pCR was assessed
using the Chi-square test. The multivariable logistic regression
model for pCR was adjusted for age at diagnosis (b50 vs ≥50 years),
tumor stage (T2 vs T3 vs T4), nodal stage (negative vs positive),
histologic grade (1 or 2 vs 3), neoadjuvant chemotherapy (FEC75/
FAC60 vs EC-D), ER (negative vs positive), PR (negative vs
positive), HER2 (normal vs amplified), TOP2A status (normal vs
amplified), and CEP17 status (normal vs duplicated). Kaplan-Meier
and log-rank analyses were used to compare DFS and OS. The Cox
proportional hazard model with a single covariate was used to obtain
the hazard ratios (HRs) for relapse or death and associated 95%
confidence interval (95% CI). HER2 (normal vs amplified),
TOP2A status (normal vs amplified), and CEP17 status (normal
vs duplicated) as individual variables were entered in a final Cox
model adjusted for traditional prognostic factors including age at
diagnosis (b50 vs ≥50 years), nodal stage (negative vs positive),
tumor size (T2 vs T3 vs T4), histologic grade (1 or 2 vs 3),
neoadjuvant chemotherapy (FEC75/FAC60 vs EC-D), ER (nega-
tive vs positive), PR (negative vs positive), and Ki67 (low vs high).
The Cox proportional hazard model was used in an exploratory
analysis of tumors to analyze tumors with either TOP2A
amplification or CEP17 duplication; we refer to these tumors
throughout the text as tumors with combined TOP2A or CEP17
duplication. A two-sided P value ≤ .05 was considered significant.Statistical analyses were performed using the SPSS 19.0 statistical
software package (SPSS, Chicago, IL).
Patient selection, assay performance, and data analysis concurred to
the reporting recommendations for tumor marker prognostic studies
(REMARK) guidelines [33].
Results
Patient Characteristics
Patient and tumor characteristics are summarized in Table 1. A
total of 101 of the 140 patients had T3 or T4 tumors (72.1%), and
93 had lymph node–positive tumors (66.4%); these factors explain
the observed low rate of conservative treatment (37.1%). A pCR after
neoadjuvant chemotherapy was achieved in 13 patients (9.3%). Four
patients (7.3%) achieved pCR after FEC75/FAC60 and nine
(10.6%) patients after EC-D treatment. No significant differences
in pCR were observed according to type of neoadjuvant treatment or
tumor stage (Supplementary Table 1).
Association ofCEP17DuplicationwithClinicopathologic Variables
Table 2 shows the associations of CEP17 status with patient
characteristics and tumor-related variables. Status of HER2, TOP2A,
and CEP17 duplication was assessable in 137 (97.9%) tumors.HER2
amplification was found in 24 samples (17.5%), TOP2A was
amplified in 7 (5.1%) of the tumors, TOP2A deletion was found in
6 samples (4.4%), and CEP17 duplication was detected in 13 (9.5%)
samples. Tumors with combined TOP2A amplification and CEP17
Table 2. Correlation between Clinicopathologic Characteristics and CEP17 Status.
Variable n (%) CEP17 Status P *
Normal Duplicated
CEP17 137 124 (90.5) 13 (9.5)
Age, years ≤50 65 (47.5) 61 (49) 4 (30.8) .206
N50 72 (52.5) 63 (51) 9 (69.2)
Menopausal status Premenopausal 63 (46) 59 (47) 4 (30.8) .247
Postmenopausal 74 (54) 65 (53) 9 (69.2)
Tumor stage II 49 (35.8) 44 (33.5) 5 (38.5) .830
III 88 (64.2) 80 (64.5) 8 (61.5)
Tumor status T2 38 (27.7) 33 (27) 5 (38.6) .606
T3 42 (30.7) 38 (30) 4 (30.7)
T4 57 (41.6) 53 (43) 4 (30.7)
Node status N0 46 (33.5) 42 (34) 4 (31) .538
N1 62 (45.5) 54 (44) 8 (61.5)
N2 25 (18) 24 (19) 1 (7.5)
N3 4 (3) 4 (3) 0 (0)
Tumor grade 1 11 (8) 11 (9) 0 (0) .499
2 62 (45) 55 (44) 7 (54)
3 64 (47) 58 (47) 6 (46)
ER Positive 86 (62.8) 77(62) 9 (69.2) .613
Negative 51 (37.2) 47 (38) 4 (30.8)
PR Positive 68 (49.6) 62 (50) 6 (46) .792
Negative 69 (50.4) 62 (50) 7 (54)
Ki67 status b20% 73 (53.3) 66 (53) 7 (54) .937
≥20% 60 (50.4) 54 (43.5) 6 (46)
Missing data 4 (2.9) 4 (3) 0 (0)
HER2 Normal 112 (82) 103 (83) 9 (69) .166
Amplification 23 (17) 19 (15) 4 (31)
Missing data 2 (1) 2 (2) 0 (0)
TOP2A Normal 124 (91) 111 (89.5) 13 (100) .220
Amplification 7 (5) 7 (5.5) 0 (0)
Deletion 6 (4) 6 (5) 0 (0)
Neoadjuvant therapy FEC75/FAC60 84 (61.3) 76 (61) 8 (61.5) .986
EC-D 53 (38.7) 48 (39) 5 (38.5)
Surgical treatment Mastectomy 86 (62.9) 78 (62.9) 8 (61.5) .923
Lumpectomy 51 (37.1) 46 (37.1) 5 (38.5)
Pathologic response Complete 12 (8.7) 9 (7.3) 3 (23) .055
Residual disease 125 (91.3) 115 (92.7) 10 (77)
* P values were calculated using the Chi-square test.
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CEP17 duplication was not associated with HER2 gene amplification
(P = .166), high grade (P = .499), ER negativity (P = .613), or a high
Ki67 (P = .937). Tumors with HER2 amplification had TOP2A
amplification in three cases (42.9%, P = .062), TOP2A deletion
in three cases (50%, P = .028), and CEP17 aneusomy in two cases
(40% P = .164). HER2 amplifications were significantly associated
with TOP2A alterations (amplifications and deletions; P = .003) and
with CEP17 aneusomy (P = .048; data not shown).Table 3. Multivariable Analysis of Predictive Factors for pCR.
Variable Score pCR
OR (95% CI) P *
ER Positive 1
Negative 7.12 (1.69-30.03) .007
TOP2A Normal 1
Amplification 6.97 (0.96-50.12) .054
CEP17 Normal 1
Duplication 6.55 (1.25-34.29) .026
HER2 Normal 1
Amplification 0.804 (0.18-3.597) .755
TOP2A/CEP17 † Normal 1
Altered 6.71 (1.66-27.01) .007
* Logistic regression models adjusted for known prognostic factors (age, nodal status, tumor size, tumor
grade, and hormone receptor status) and neoadjuvant therapy.
† Tumors with combined TOP2A amplification and CEP17 duplication.Association of Clinicopathologic Parameters with pCR
In the multivariable analysis, CEP17 duplication associated
with a high percentage of pCR [odds ratio (OR) 6.55, 95% CI
1.25-34.29, P = .026] and TOP2A gene amplification showed a
benefit with borderline significance (OR 6.97, 95% CI 0.96-
50.12, P = .054; Table 3). When TOP2A amplifications and
CEP17 duplication were combined, we observed a significant
association with pCR (OR 6.71, 95% CI 1.66-27.01, P = .007;
Table 3). We did not find a significant difference in the benefit of
treatment with anthracyclines when assessing deletion (P = .429) or
combined TOP2A amplifications and deletions (P = .089) in
univariable analysis. HER2 amplifications showed no direct
association with pCR (P = .144). When pCR was assessed
according to treatment received (Supplementary Table 1),
CEP17 duplications were the only factor associated with better
response to FEC70/FAC65 in both univariable (P = .004) and
multivariable analyses (OR 14, 95% CI 1.427-137.324, P = .025).
Meanwhile, the multivariable analysis showed that ER status (OR
12.68, 95% CI 1.427-137.324, P = .011) and TOP2A/CEP17
(OR 6.31, 95% CI 1.981-81.186, P = .007) were associated with
better response to EC-D (data not shown).
Prognostic Associations with DFS and OS
The univariable analysis showed that CEP17 duplication, HER2
amplification, and TOP2A amplification were not significantly
associated with DFS or OS (Table 4). However, when TOP2A
amplification and CEP17 duplication were combined, Kaplan-Meier
and log-rank analyses showed a significant association with better
DFS (P = .026) and a borderline non-significant trend with OS (P =
.054; Figure 1). The univariable analysis showed a similar association
of the combination of TOP2A amplification and CEP17 duplication
with DFS (HR 4.34, 95% CI 1.05-17.92, P = .042) and OS (HR
3.70, 95% CI 0.89-15.34, P = .071; Table 4). However, after
adjustment for the classic prognostic factors, age, and neoadjuvant
therapy, the multivariable analysis showed that CEP17 duplication,
TOP2A amplification, HER2 amplification, and the combination of
TOP2A amplifications and CEP17 duplication failed to show an
association with DFS or OS (Table 5).
Discussion
The main finding in this study is that CEP17 duplication associates
with pCR to anthracycline-based neoadjuvant therapy in patients
with breast cancer. To our knowledge, this is the first study to analyze
the association of CEP17 duplication with response to neoadjuvantTable 4. Biomarker Analysis and Relation with DFS and OS.
Variable Score n DFS OS
HR (95% CI) P HR (95% CI) P *
CEP17 Normal 124 1 1
Duplicated 13 2.64 (0.64-10.9) .179 2.42 (0.58-10.02) .223
HER2 Normal 113 1 1
Amplified 24 0.97 (0.45-2.08) .960 0.96 (0.44-2.06) .907
TOP2A Non-amplified 130 1 1
Amplified 7 21.9 (0.92-5275) .269 21.73 (0.04-11545) .336
Ki67 ≥20% 60 1 1
b20% 74 1.89 (1.04-3.46) .036 1.91 (1.02-3.58) .044
TOP2A/CEP17 † Normal 117 1 1
Altered 20 4.35 (1.05-17.93) .042 3.71 (0.89-15.34) .071
* Univariable Cox proportional hazard models based on 136 patients, 44 recurrences, and 40 deaths.
† Tumors with combined TOP2A amplification and CEP17 duplication.
Figure 1. Association of combined TOP2A amplification and CEP17
duplication with patient outcome. DFS (A) and OS (B) Kaplan-Meier
curves and log-rank tests according to the presence or absence of
tumors with combined TOP2A amplification and CEP17 duplication.
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Our rationale in investigating the association of CEP17 duplication
and response to chemotherapy was based on the recognition thatTable 5. Multivariable Analyses for All Prognosis Variables and Relation with DFS and OS.
Variables DFS OS
HR (95% CI) P HR (95% CI) P *
Age (b50 vs ≥50 years) 1.03 (0.5-2.15) .91 1.09 (0.5-2.41) .81
Lymph nodes (negative vs positive) 2.95 (1.23-7.07) .01 3.12 (1.21-8.03) .01
Tumor size (T2 vs T3 vs T4) 1.78 (0.85-3.7) .02 1.63 (0.68-3.91) .9
Tumor grade (1 vs 2 vs 3) 1.53 (0.77-3.03) .22 2.07 (1.06-4.05) .03
ER (positive vs negative) 2.20 (1.24-4.01) .01 1.95 (0.93-4.07) .07
pCR (positive vs negative) 4.41 (0.54-30.65) .08 4.49 (0.58-34.72) .15
Ki67 (b20% vs ≥20%) 1.29 (0.65-2.54) .45 1.33 (0.65-2.71) .43
Treatment (EC-D vs FEC/FAC) 1.17 (0.61-2.24) .62 1.07 (0.54-2.12) .83
CEP17 (duplicated vs normal) 2.46 (0.54-11.06) .24 2.29 (0.51-10.35) .27
HER2 (amplified vs normal) 1.23 (0.51-2.97) .63 1.06 (0.43-2.62) .89
TOP2A/CEP17 † (altered vs normal) 3.91 (0.89-17.2) .71 3.72 (0.84-16.43) .08
* Multivariable Cox proportional analysis based on 136 patients, 44 recurrences, and 40 deaths.
† Tumors with combined TOP2A amplification and CEP17 duplication.CEP17 duplication could be a potential marker of genomic instability
and DNA repair dysfunction [26,34]. Chromosome 17 is the second
highest density gene in the human genome, and it includes several key
genes that have a role in breast cancer (HER2, TOP2A, BRCA1,
and Tau) and DNA repair (P53, RAD51C, and RAD52B) [35,36].
Analyses of rearrangement have shown that chromosome 17 harbors a
region of high genomic instability centered around 17q12 and
characterized by multiple gene amplifications and deletions [37–39].
This pattern has traditionally been associated with polysomies of
chromosome 17. However, recent data using array comparative
genomic hybridization suggest that chromosome 17 polysomies
detected by FISH or CISH are in fact very rare in breast cancer; what
is being detected are gains or amplification in the centromere region
of chromosome 17 rather than a copy number gain of the whole
chromosome 17 [24,25]. An increase in the copy numbers of CEP17
might cause several key genetic changes, such as HER2 amplification,
TOP2A amplification or deletion, P53 loss, and BRCA1 loss. All
these chromosome abnormalities have been linked to mechanisms of
breast tumorigenesis including cell proliferation, tumor angiogenesis,
and reduced apoptosis [38,39]. Together, these findings suggest that
CEP17 duplication is an indicator of genetic instability around 17q12
locus that could be linked to aberrations in the copy number of DNA
repair genes, such as TOP2A. Therefore, analysis of CEP17
duplication may allow for an improvement of treatment efficacy
based on therapies targeting DNA repair genes.
Our results showed that CEP17 duplication was present in 9.3%
of the tumors, a result that is somehow inferior to results reported by
others. However, the interlaboratory reproducibility of CEP17
testing is unknown, and the prevalence differs among studies,
ranging from 8% to 68% depending on the type of material
examined, cell counting methods, and the threshold criteria for
CEP17 duplication [36]. Moreover, there are conflicting results in
earlier studies in relation to the correlation between CEP17
duplication and a more aggressive tumor phenotype [36]. Our
results did not show an association between CEP17 duplication and
high tumor grade, lymph node metastasis, ER negativity, HER2
amplification, or high Ki67.
Another finding of interest in our study is that TOP2A gene
amplification correlated with pCR to anthracycline-based neoad-
juvant therapy. However, the response was of borderline
significance (OR 6.97, 95% CI 0.96-50.12, P = .054), but when
combined with CEP17 duplication, the pCR response was
significant (OR 6.71, 95% CI 1.66-27.01, P = .007). The small
number of patients in our study might explain that TOP2A gene
amplification alone (found in only 5% of tumors) was not
associated with pCR. These observations suggest that patients
with tumors that harbor gene alterations that may increase TOP2A
copy number benefit more from anthracycline-based neoadjuvant
therapy. We hypothesized that anthracycline sensitivity is not only
the result of an increased number of genes secondary to gene
amplification of TOP2A but also the result of concomitant gains in
pericentromeric regions on chromosome 17 (CEP17 duplication).
Thus, CEP17 duplication would be an indirect mechanism of
increasing TOP2A gene copy number. However, we cannot yet
identify which of these chromosomal abnormalities might be
associated with the underlying mechanism of chemosensitivity.
As in previous studies [40,41], we found that HER2 amplifica-
tion failed to have a predictive value, supporting that patients with
HER2-negative tumors may benefit from treatment with
866 CEP17 Duplication and Responsiveness in Breast Cancer Tibau et al. Neoplasia Vol. 16, No. 10, 2014anthracyclines. We also observed that patients with TOP2A normal
tumors might have some additional benefit from treatment with
anthracyclines. Our results suggest that other mechanisms, such as
the immune response, tumor-stromal interactions, and CEP17
duplication, may participate in the increased sensitivity to
anthracyclines in these patients [42–45]. Therefore, the use of
anthracyclines should not be limited to patients with HER2
amplification or TOP2A amplification.
We were unable to identify any statistically significant relationship
between CEP17 duplication and patient outcome. Our results are
consistent with two previous studies [21,27] that analyzed prognostic
and predictive associations of CEP17 duplication in early-stage
breast cancer patients treated with adjuvant chemotherapy regimens
containing anthracyclines and non-anthracyclines. Bartlett et al. [21]
assessed the role of CEP17 duplication in 1931 tumors from 2391
women enrolled onto the UK National Epirubicin Adjuvant Trial
(NEAT/BR9601). Interestingly, although this study also failed to
find a significant association of CEP17 duplication with patient
prognosis (DFS HR 1.12, 95% CI 0.92-1.36, P = .24, OS HR 1.17,
95% CI 0.95-1.44, P = .13), it showed that the benefit on survival
from the addition of epirubicin was confined to tumors with CEP17
duplication. Similar results were obtained by Pritchard et al. [27] in
the randomized controlled mammary 5 (MA.5) adjuvant trial. The
results did not identify a significant association of CEP17 with risk of
recurrence (HR 1.15, 95% CI 0.86-1.54, P = .34) or risk of death
(HR 1.39, 95% CI 0.90-2.15, P = .14) in multivariable analysis.
However, in patients whose tumors exhibit CEP17 duplication and
who received anthracyclines, there was a significant benefit for
recurrence-free survival (HR 0.59, 95% CI 0.37-0.92, P = .02) and
OS (HR 0.61, 95% CI 0.37-1.01, P = .05) in univariable analysis.
This association disappeared after adjustment for other variables.
The potential limitations of our study are the restricted sample size
and the retrospective design, which could bias patient selection. In
addition, the absence of a study group receiving non-anthracycline-
based chemotherapy meant we were unable to distinguish whether the
pCR rate was attributed to higher sensitivity to anthracyclines or to
chemotherapy with anthracyclines, taxanes, cyclophosphamide, and/or
5-fluorouracil. These results are therefore preliminary and require
confirmation in larger prospective studies specifically designed to
validate the predictive role of these biomarkers and to compare regimens
with and without anthracyclines.
In conclusion, our results suggest that CEP17 duplication may be a
useful biomarker of sensitivity to neoadjuvant anthracycline-based
chemotherapy. A better understanding of CEP17 abnormalities might
help to select patients who benefit most from anthracycline-based
chemotherapy regimens and to identify patients in whom toxicity
from these drugs could be avoided.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.08.012.
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